Positive News SentimentPositive NewsNASDAQ:RZLT Rezolute (RZLT) Stock Price, News & Analysis $4.46 +0.11 (+2.53%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Rezolute Stock (NASDAQ:RZLT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rezolute alerts:Sign Up Key Stats Today's Range$4.28▼$4.7150-Day Range$3.11▼$4.4352-Week Range$2.22▼$6.19Volume2.22 million shsAverage Volume636,057 shsMarket Capitalization$381.42 millionP/E RatioN/ADividend YieldN/APrice Target$11.83Consensus RatingBuy Company OverviewRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Read More… Rezolute Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreRZLT MarketRank™: Rezolute scored higher than 62% of companies evaluated by MarketBeat, and ranked 405th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingRezolute has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRezolute has only been the subject of 2 research reports in the past 90 days.Read more about Rezolute's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Rezolute are expected to decrease in the coming year, from ($0.93) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rezolute is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rezolute is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRezolute has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Rezolute's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.36% of the float of Rezolute has been sold short.Short Interest Ratio / Days to CoverRezolute has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Rezolute has recently increased by 16.03%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRezolute does not currently pay a dividend.Dividend GrowthRezolute does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.36% of the float of Rezolute has been sold short.Short Interest Ratio / Days to CoverRezolute has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Rezolute has recently increased by 16.03%, indicating that investor sentiment is decreasing significantly. News and Social Media4.2 / 5News Sentiment1.59 News SentimentRezolute has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Rezolute this week, compared to 3 articles on an average week.Search Interest9 people have searched for RZLT on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat Follows2 people have added Rezolute to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Rezolute insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,060,930.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders18.39% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.97% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rezolute's insider trading history. Receive RZLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter. Email Address RZLT Stock News HeadlinesBrian Kenneth Roberts Buys 2,500 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockJune 27 at 7:49 AM | insidertrades.comInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 5,000 Shares of StockJune 25, 2025 | insidertrades.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.June 30 at 2:00 AM | Porter & Company (Ad)Young-Jin Kim Buys 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockJune 24, 2025 | insidertrades.comInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Acquires 1,230,769 Shares of StockJune 26, 2025 | americanbankingnews.comRezolute, Inc. (NASDAQ:RZLT) is a favorite amongst institutional investors who own 77%June 3, 2025 | finance.yahoo.comRezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital HyperinsulinismMay 28, 2025 | globenewswire.comRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateMay 21, 2025 | finanznachrichten.deSee More Headlines RZLT Stock Analysis - Frequently Asked Questions How have RZLT shares performed this year? Rezolute's stock was trading at $4.90 at the start of the year. Since then, RZLT stock has decreased by 9.0% and is now trading at $4.46. View the best growth stocks for 2025 here. How were Rezolute's earnings last quarter? Rezolute, Inc. (NASDAQ:RZLT) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.05. How do I buy shares of Rezolute? Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rezolute own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rezolute investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Advanced Micro Devices (AMD), Taiwan Semiconductor Manufacturing (TSM), CrowdStrike (CRWD) and Vanguard S&P 500 ETF (VOO). Company Calendar Last Earnings5/13/2025Today6/30/2025Fiscal Year End6/30/2025Next Earnings (Estimated)9/18/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RZLT CIK1509261 Webwww.rezolutebio.com Phone(650) 206-4507FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$11.83 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+165.3%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$68.46 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.09% Return on Assets-63.08% Debt Debt-to-Equity RatioN/A Current Ratio8.43 Quick Ratio8.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.19 per share Price / Book2.04Miscellaneous Outstanding Shares85,520,000Free Float69,792,000Market Cap$381.42 million OptionableOptionable Beta1.04 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:RZLT) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredConsumer apocalypse imminent (7 ominous red flags)The #1 Gold play right now (not a miner, ETF, or bullion) Gold is up 237% since 2008... but one gold invest...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.